Neoadjuvant chemotherapy of invasive bladder cancer

Abstract

A total of 40 chemonaive patients with invasive transitional cell carcinoma received gemcitabine 2 400 mg/m2 on days 1, 8 and 15 plus cisplatin 100 mg/m2 on day 2 as a presurgery treatment. Cisplatin in a single dose of 20 mg/m2 administered into pubic. Grade 3 hematologic toxicity was in 27,5% of patients. The effectiveness of neoadjuvant chemotherapy was 73%.

Keywords

• инвазивный рак мочевого пузыря
• неоадъювантная химиотерапия
• цисплатин
• гемцитабин